Immune globulin therapy in primary immunodeficiency
- Jordan S Orange, MD, PhD
Jordan S Orange, MD, PhD
- Section Editor — Immunology and Immunodeficiency
- Professor of Pediatrics
- Chief of Immunology, Allergy, and Rheumatology
- Baylor College of Medicine
- Texas Children's Hospital
Polyclonal immune globulin consists of immunoglobulins (mostly immunoglobulin G [IgG]) purified from pooled human plasma. Immune globulin is used to treat a wide variety of diseases, including primary and secondary immunodeficiency states and hematologic and autoimmune disorders .
Terminology — Immune globulin, intravenous (human) will be referred to as "IVIG" in this review because this term is commonly used by clinicians, although the abbreviation preferred by various regulatory agencies is "IGIV." Immune globulin can also be administered subcutaneously. Immune globulin, subcutaneous (human) will be referred to as "SCIG."
The use of immune globulin in primary immunodeficiency will be reviewed here. General principles in the use of IVIG and SCIG and the role of these agents in the treatment of various hematologic and autoimmune disorders are presented separately. (See "Overview of intravenous immune globulin (IVIG) therapy".)
Comparisons of intravenous and subcutaneous therapy, both traditional and hyaluronidase-facilitated, are discussed elsewhere. (See "Subcutaneous and intramuscular immune globulin therapy".)
Immune globulin therapy is the mainstay of treatment for a variety of primary immunodeficiency states [1-3].To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol 2017; 139:S1.
- Guidelines for IVIG administration in the United Kingdom. www.ivig.nhs.uk/documents/Clinical%20Guidelines%20SECOND%20EDITION%20(3).pdf (Accessed on January 07, 2009).
- Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186.
- Perez E, Bonilla FA, Orange JS, Ballow M. Specific Antibody Deficiency: Controversies in Diagnosis and Management. Front Immunol 2017; 8:586.
- Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol 2017; 188:333.
- Picard C, Al-Herz W, Bousfiha A, et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol 2015; 35:696.
- US FDA: Guidance for industry: Safety, efficacy and pharmacokinetic studies to support marketing of IGIV (human) as replacement therapy for primary humoral immunodeficiency. www.fda.gov.cber/gdlns/igivimmuno.pdf (Accessed on October 10, 2008).
- Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109:1001.
- Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354.
- Berger M. Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD. J Clin Immunol 2011; 31:924.
- Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 2010; 137:21.
- Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012; 169:172.
- de Gracia J, Vendrell M, Alvarez A, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004; 4:745.
- Rider NL, Kutac C, Hajjar J, et al. Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment. J Clin Immunol 2017; 37:461.
- Seeborg FO, Seay R, Boyle M, et al. Perceived Health in Patients with Primary Immune Deficiency. J Clin Immunol 2015; 35:638.
- ONCLEY JL, MELIN M. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma. J Am Chem Soc 1949; 71:541.
- KISTLER P, NITSCHMANN H. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962; 7:414.
- Washburn N, Meccariello R, Hu S, et al. High-resolution physicochemical characterization of different intravenous immunoglobulin products. PLoS One 2017; 12:e0181251.
- Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence. Autoimmun Rev 2016; 15:71.
- Hachulla E. [IgIV at home:experience of a center--economic aspects]. Rev Med Interne 2007; 28 Spec No. 1:7.
- Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy 2017; 9:1035.
- Buehler AM, Flato UP, Ferri CP, Fernandes JG. Is there evidence for recommending specific intravenous immunoglobulin formulations? A systematic review of head-to-head randomized controlled trials. Eur J Pharmacol 2015; 747:96.
- Hayakawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 2002; 118:1187.
- Hernandez-Trujillo HS, Chapel H, Lo Re V 3rd, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol 2012; 169:57.
- Shapiro RS, Wasserman RL, Bonagura V, Gupta S. Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes. J Clin Immunol 2017; 37:190.
- Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122:210.
- Rojavin MA, Hubsch A, Lawo JP. Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency. J Clin Immunol 2016; 36:210.
- Hajjar J, Guffey D, Minard CG, Orange JS. Increased Incidence of Fatigue in Patients with Primary Immunodeficiency Disorders: Prevalence and Associations Within the US Immunodeficiency Network Registry. J Clin Immunol 2017; 37:153.
- Misbah SA. Effective dosing strategies for therapeutic immunoglobulin: managing wear-off effects in antibody replacement to immunomodulation. Clin Exp Immunol 2014; 178 Suppl 1:70.
- Jolles S, Orange JS, Gardulf A, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol 2015; 179:146.
- Kurecová B, Janků P, Litzman J. [Common variable immunodeficiency in pregnancy (set of case reports)]. Ceska Gynekol 2009; 74:197.
- Gardulf A, Andersson E, Lindqvist M, et al. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. J Clin Immunol 2001; 21:150.
- Palmeira P, Costa-Carvalho BT, Arslanian C, et al. Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin. Pediatr Allergy Immunol 2009; 20:528.
- Berger M, Cupps TR, Fauci AS. High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy. JAMA 1982; 247:2824.
- B cell immunodeficiencies
- Combined immunodeficiencies
- Other specific primary immunodeficiencies
- Prevention of bacterial infections
- Other benefits
- Limitations of therapy
- CONSTITUENTS AND PRODUCTION METHODS
- Antibodies to specific antigens
- Other constituents
- INFORMED CONSENT/PATIENT INFORMATION
- Risks of therapy
- ADMINISTRATION AND DOSING
- Selecting a specific product
- Pretreatment testing
- Initial doses and schedules
- Trough levels
- Individualizing the dose
- - Determining a patient's threshold dose
- - "Wear-off" effects
- Patients with normal pretreatment IgG levels
- Monitoring and record keeping
- Duration of therapy
- Use in pregnancy
- SOCIETY GUIDELINE LINKS
- SUMMARY AND RECOMMENDATIONS